AVEO Pharma (AVEO) to Present Data from Tivozanib at AACR 12

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and preclinical data on AV-203, AVEO’s ErbB3 inhibitory antibody, will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31-April 4, 2012 in Chicago.

For the schedule, click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Acrivon Therapeutics (ACRV) Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
• Ball Corporation (BALL) Raises Dividend, Enters 40M Share Buyback, Announces Management Changes
• Boeing (BA) Statement on U.S. Air Force Collaborative Combat Aircraft Announcement